Lignospan Forte

Product NDC: 51004-1096
11-digit product format: 510041096
Labeler code: 51004
Product ID: 51004-1096_0dc2796a-c3b3-48f3-b5e3-277d7646ca54
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Lidocaine Hydrochloride and Epinephrine Bitartrate
Dosage form: INJECTION, SOLUTION
Route: SUBCUTANEOUS
Labeler: Novocol Pharmaceutical of Canada, Inc.
Application: ANDA088389
Marketing category: ANDA
Marketing start: 2011-10-15
Marketing end: 0000-00-00
Substance: LIDOCAINE HYDROCHLORIDE ANHYDROUS; EPINEPHRINE BITARTRATE
Active strength: 20 mg/mL; mg/mL
Pharmacologic classes: Amide Local Anesthetic [EPC],Amides [CS],Antiarrhythmic [EPC],Local Anesthesia [PE],Adrenergic alpha-Agonists [MoA],Adrenergic beta-Agonists [MoA],alpha-Adrenergic Agonist [EPC],beta-Adrenergic Agonist [EPC],Catecholamine [EPC],Catecholamines [CS]
NDC exclude flag: E
Listing certified through: 2018-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	51004-1096		D	Discontinued by firm		2026-08-03
excluded package	package	51004-1096	51004-1096-7	D	Discontinued by firm		2026-08-03

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 30 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	51004-1096-7	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	51004-1096-7	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	51004-1096-7	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	51004-1096-7	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	51004-1096-7	D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	51004-1096-7	D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	51004-1096-7	D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	51004-1096-7	D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	51004-1096-7	D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	51004-1096-7	D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	51004-1096-7	D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	51004-1096-7	D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded product	product		I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	51004-1096-7	I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded product	product		I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	51004-1096-7	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded product	product		E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded package	package	51004-1096-7	E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
A088389-001	LIGNOSPAN FORTE	EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION		RLD, RS	1985-01-22

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 41 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RS	1985-01-22	`ea99ee380514…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`1c564ffb4f44…`
2023-12-20 04:57 UTC	2023-12	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`ea1830bbd6c7…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`a72a2bbeb626…`
2023-10-25 00:34 UTC · 2 captures of this ZIP	2023-10	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`9b2671bbb829…`
2023-07-15 15:27 UTC · 2 captures of this ZIP	2023-07	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`a67488948f0b…`
2023-06-13 01:57 UTC · 3 captures of this ZIP	2023-06	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`3f0d92c62455…`
2023-05-13 08:27 UTC	2023-05	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`053a50430f4f…`
2023-01-26 05:58 UTC	2023-01	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`3bdfa0b2c4d7…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`3a93d1ddd44b…`
2022-10-28 04:53 UTC	2022-10	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	A088389-001	LIGNOSPAN FORTE	EQ 0.02MG BASE/ML;2%	INJECTABLE / INJECTION	RLD, RS	1985-01-22	`cb3db0bc1861…`

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
51004-1096-7	2021-12-07	C162847	48780-1	9d75b9d0-a702-f424-e053-dadaa90a57ce	LIGNOSPAN FORTE (Lidocaine HCl 2% and Epinephrine 1:50,000 Injection) LIGNOSPAN STANDARD (Lidocaine HCl 2% and Epinephrine 1:100,000 Injection) (Lidocaine hydrochloride and epinephrine injection, USP)
51004-1096-7	2020-01-31	C162847	48780-1	9d75b9d0-a702-f424-e053-dadaa90a57ce	LIGNOSPAN FORTE (Lidocaine HCl 2% and Epinephrine 1:50,000 Injection) LIGNOSPAN STANDARD (Lidocaine HCl 2% and Epinephrine 1:100,000 Injection) (Lidocaine hydrochloride and epinephrine injection, USP)

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
Epinephrine Bitartrate	ACTIVE INGREDIENT	30Q7KI53AK	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
LIDOCAINE HYDROCHLORIDE ANHYDROUS	ACTIVE INGREDIENT	EC2CNF7XFP	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
Epinephrine	ACTIVE MOIETY	YKH834O4BH	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
LIDOCAINE	ACTIVE MOIETY	98PI200987	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
Edetate Disodium	INACTIVE INGREDIENT	7FLD91C86K	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
Potassium Metabisulfite	INACTIVE INGREDIENT	65OE787Q7W	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
Sodium Chloride	INACTIVE INGREDIENT	451W47IQ8X	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
Sodium Hydroxide	INACTIVE INGREDIENT	55X04QC32I	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3
Water	INACTIVE INGREDIENT	059QF0KO0R	LIGNOSPAN FORTE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [NOVOCOL PHARMACEUTICAL OF CANADA, INC.]	3

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 7 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Lidocaine	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	Benco Dental	9419ac39-9b26-4cca-a2d6-167205fede24	2026-07-28	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 088389 application number: ANDA088389
Lidocaine	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	Darby Dental Supply, LLC	27e8fdfb-e923-4f99-aff7-8b9e50228151	2026-07-27	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 088389 application number: ANDA088389
Lidocaine	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	Patterson Dental	f074c0dc-7c3f-46fd-a480-b8337a19fe5c	2026-07-27	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 088389 application number: ANDA088389
LIDOCAINE	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	Henry Schein Inc.	1ca96c77-d983-496b-84a6-54709e80f532	2026-04-23	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 088389 application number: ANDA088389
Lignospan Forte	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE	Septodont, Inc.	f8ca7d03-01c8-450f-9279-59789c3497ea	2025-03-20	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 088389 application number: ANDA088389
Xylocaine	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	Dentsply Pharmaceutical	14b55cf9-f7cd-4bb4-a7c5-aba61abadef1	2024-02-05	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 088389 application number: ANDA088389
Lidocaine	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE	Septodont, Inc.	df130310-41db-45df-a214-9da01cf0bf41	2024-02-05	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 088389 application number: ANDA088389

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
EC2CNF7XFP	LIDOCAINE HYDROCHLORIDE ANHYDROUS	73-78-9	LIDOCAINE HYDROCHLORIDE ANHYDROUS
30Q7KI53AK	EPINEPHRINE BITARTRATE	51-42-3	EPINEPHRINE BITARTRATE

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Lignospan Forte	Novocol Pharmaceutical of Canada, Inc.	2015-09-18	HUMAN PRESCRIPTION DRUG LABEL	3